10
Aug

Compound Shows Promise as Next-Generation Prostate Cancer Therapy

DURHAM, find N.C. — In the search for new ways to attack recurrent prostate cancer, researchers at Duke Health report that a novel compound appears to have a unique way of blocking testosterone from fueling the tumors in mice.

The potential foundation for a next-generation therapy, called tetraaryl cyclobutane, or CB, is being studied as an option for prostate tumors that have grown resistant to current anti-androgen drugs, notably enzalutamide.

“Prostate cancer is the most prevalent form of cancer in men, and the principal driver of tumor growth is the androgen receptor,” said John D. Norris, Ph.D., associate research professor in the Department of Pharmacology & Cancer Biology at Duke and senior author of a study published online Aug. 8 in the journal Nature Chemical Biology.

Click here to read more